In this study, we aimed to assess the risk of pneumocystosis among HIV-infected patients with baseline CD4 counts of <200 cells/μL who discontinued primary or secondary prophylaxis before their CD4 counts increased to ≧200 cells/μL after receipt of HAART. This evidence concerns the gene CD4 and pneumocystosis.